IMPACT OF INVASIVE EEG MONITORING AND RESECTIVE NEUROSURGICAL TREATMENT ON THE QUALITY OF LIFE IN PATIENTS WITH DRUG RESISTANT EPILEPSY - PRELIMINARY RESULTS

Dragana Mijatović1,2, Željka Petelin Gadže3, Filip Derke4, Goran Mrak5, Ratimir Petrović6 & Andrica Lekić7

1Istrian Health Center, Umag Section, Umag, Croatia
2School of Medicine, University of Rijeka, Rijeka, Croatia
3Department of Neurology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Referral Centre of the Ministry of Health of the Republic of Croatia for Epilepsy, Zagreb, Croatia
4Health Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia
5Department of Neurosurgery, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia
6Department of Nuclear Medicine and Radiation Protection, University Hospital Zagreb, Zagreb, Croatia
7Department of Basic Medical Sciences, Faculty of Health Studies, University of Rijeka, Rijeka, Croatia

received: 12.9.2019; revised: 21.10.2019; accepted: 3.12.2019

SUMMARY

Background: Neurosurgical treatment is one of important ways to cure drug resistant epilepsy. After invasive EEG monitoring and the invasive neurosurgical treatment (resective surgery) there are possible complications (intracranial haemorrhage, cortical lesions and infections), however there are possible neurophysiological outcomes such as memory outcomes, language outcomes and psychiatric outcomes. The quality of life in epilepsy (QOLIE-31) scale is a self-completed questionnaire which contains seven subscales which address the following aspects: emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects and overall quality of life. Our study aimed to examine the quality of life in patients with drug resistant epilepsy who had undergone invasive EEG monitoring and resective neurosurgical treatment through the application of the QOLIE-31 scale.

Subjects and methods: The study included 9 patients with drug resistant epilepsy who had undergone invasive EEG monitoring followed by resective neurosurgical treatment in the period from 2010 to 2016, and the control group of 15 patients with drug resistant epilepsy who had not undergone neurosurgical procedures. Clinical variables of interest for this study were obtained through phone contact, and the QOLIE-31 scale was applied.

Results: In the domain of seizure worry, patients in the examined group were more concerned about the seizures (54.7) compared to the examined group (80), as well as in the overall quality of life (examined group 57.5; control group 77.5). Patients in the control group complained more in the domain of antiepileptic therapy (score 70.7) than patients in the examined group (score 100). In the other domains: emotional well-being, energy/fatigue, cognitive functioning, and social functioning there were minor deviations between the examined and control groups.

Conclusion: There was no statistically significant difference between individual QOLIE-31 questionnaires, as well as between the two groups of respondents.

Key words: drug resistant epilepsy - invasive EEG monitoring - epilepsy surgery - QOLIE-31

Abbreviations: AED - antiepileptic drug; CSF - cerebrospinal fluid; EEG - electroencephalography; MRI - magnetic resonance imaging; QoL - quality of life; QOLIE-31 - quality of life in epilepsy 31; VNS - vagus nerve stimulator

INTRODUCTION

Epilepsy is one of the most common chronic neurologic disease, affecting about 50 million patients worldwide, and around 6 million patients in Europe (Hajnšek 2010). The main precondition for successful treatment of epilepsy is a timely etiological evaluation of disease and clinical phenotype verification, but also the earlist start of treatment with appropriate antiepileptic therapy at the optimal dose, with a view to completely stop epileptic seizures. It is estimated that 30% to 40% of patients suffer from drug resistant epilepsy, a form of epilepsy in which with at least two optimally selected and regularly taken antiepileptics, at an appropriate dose, the complete release of epileptic seizures has not occurred (Hajnšek et al. 2010, Kwan et al. 2010).

An increasing number of studies have shown that surgery of epilepsy plays an important role in the treatment of drug-resistant epilepsy. Moreover, the comprehensive treatment mainly based on surgery can achieve the remission and even cure of drug resistant epilepsy (Sheng 2018).
Very important is careful selection of patients with drug resistant epilepsy who are candidates for preoperative examination before invasive (classic neurosurgical resection) or minimally invasive neurological treatment (implantation of vagus nerve stimulator (VNS)) (Schramm et al. 2008, Petelin et al. 2010, Miller et al. 2013, Yamamoto 2015, Sheng 2018). Seizure recurrence after resection follows predictable slopes based on multiple factors, including the duration of epilepsy, history of generalised tonic seizures, frequency of preoperative seizures, and the presumptive pathological cause of epilepsy on magnetic resonance imaging (MRI) (Miller et al. 2013, Yamamoto 2015, Najm 2018). Because of these facts patients with drug resistant epilepsy are candidates for detailed preoperative examination before neurological treatment (Najm 2018).

In the preoperative evaluation of patients with drug resistant epilepsy, diagnostic techniques can be divided into noninvasive and invasive. The invasive EEG monitoring can be performed during surgery to optimise delineation of the epileptogenic area by taking into account interictal spikes and spike patterns while reducing resection volume. This may reduce neurological deficits and yield a better quality of life (McKhann et al. 2000, Schramm et al. 2008, Petelin et al. 2010, Miller et al. 2013, Yamamoto 2015, Najm 2018).

After the invasive EEG monitoring and neurological treatment (resective surgery) there are possible complications (intracranial haemorrhage, cerebrospinal fluid (CSF) leak, cortical lesions and infections) and neuropsychologic outcomes such as memory outcome, language outcomes and psychiatric outcomes (Fong et al. 2012, Hader et al. 2013, Van ’t Klooster et al. 2015).

The Quality of life in epilepsy - (QOLIE-31) is a self-completed questionnaire designed for adult epileptic patients (18 years or older). We used the QOLIE-31 validated Croatian 1.0 version. It contains seven subscales which address the following aspects: emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects and overall quality of life (Lušić et al. 2011).

SUBJECTS AND METHODS

We conducted a cross-sectional study. The study included 9 patients with drug resistant epilepsy who had undergone invasive EEG monitoring followed by resective neurosurgical treatment in the period from 2010 to 2016, and the control group of 15 patients with drug resistant epilepsy who had not undergone neurological procedures. Both groups were followed at the University Hospital Centre Zagreb, Referral Centre for Epilepsy of the Ministry of Health of the Republic of Croatia.

Clinical variables of interest for this study were obtained through phone contact, and the QOLIE-31 scale was applied. The domains examined in QOLIE-31 are: seizure worry (5 questions), overall quality of life (2 questions), emotional well-being (5 questions), energy/fatigue (4 questions), cognitive functioning (6 questions), medication effects (3 questions), social functioning (5 questions), and patients health status (1 questions). The patients answer by circling the appropriate number (1,2,3…) in response to the question, and if he is not sure can write a comment or explanation next to the question asked. Due to the different meaning of the answers to the question asked, a scoring system was developed that involves the conversion of numerical answers to a scale of 0-100 points.

In the case group only 4 patients accepted to participate in our study. All 4 patients had positive brain MRI 3T, focal cortical dysplasia (FCD).

In the control group we collected 15 properly filled QOLIE-31 questionnaires. These were patients with drug resistant epilepsy and with negative brain MRI 3T, in whom the invasive EEG monitoring was not performed.

In the statistical analysis of data we used the Mann-Whitney U test of nonparametric tests for independent samples. All statistical analyses were performed using Statistica version 13 (StatSoft Inc., Tulsa, OK, USA.).

RESULTS

The QOLIE-31 questionnaire was completed by 4 patients (2 females, 2 males, mean age 22.5 years) who had undergone invasive EEG monitoring, and by 15 patients (7 females, 8 males, mean age 46 years) in control group. We compared the two groups in terms of personal characteristics (education, working status, marital status and place of living).

According to the degree of education in the examined group, there were patients with secondary education, of which 2 were active and 2 unemployed. All 4 patients did not have marital cohabitation (2 married, 2 unmarried), but all had a place of living (2-house / 2 -apartment).

According to the level of education in the control group, most of the patients were with high school education (8) and work-active (9), but there were patients with higher (1) and higher education (1) and also special needs school (1). According to marital status, 6 patients were married and 6 were single (2 unmarried, 1 widowed, 1 divorced), and the majority had a place of living (5 house / 7 apartment) (Table 1).

We studied the difference among QOLIE-31 domains between the patients undergoing invasive EEG monitoring and those who did not. The test results are listed in Table 2.
Table 1. General data of patients

<table>
<thead>
<tr>
<th></th>
<th>Examined group</th>
<th>Control group</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>22.5 (20.5-25)</td>
<td>46 (32-53)</td>
<td>0.014</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td>0.906</td>
</tr>
<tr>
<td>female</td>
<td>2</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>male</td>
<td>2</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td><strong>Education</strong></td>
<td></td>
<td></td>
<td>0.398</td>
</tr>
<tr>
<td>high school education</td>
<td>4</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>college education</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>high qualification</td>
<td>0</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>else</td>
<td>0</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td><strong>Marital status</strong></td>
<td></td>
<td></td>
<td>0.031</td>
</tr>
<tr>
<td>married</td>
<td>0</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>not married</td>
<td>4</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>else</td>
<td>0</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td><strong>Habitation</strong></td>
<td></td>
<td></td>
<td>0.592</td>
</tr>
<tr>
<td>house</td>
<td>2</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>apartment</td>
<td>2</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>else</td>
<td>0</td>
<td>3</td>
<td></td>
</tr>
</tbody>
</table>

*Median (lower quartile-upper quartile)

Table 2. QOLIE-31 scale

<table>
<thead>
<tr>
<th>QOLIE - 31</th>
<th>All (N=19)</th>
<th>Examined group (N=4)</th>
<th>Control group (N=15)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizure worry</td>
<td>75 (46-93.4)</td>
<td>54.7 (35-83)</td>
<td>80 (55.8-93.4)</td>
<td>0.422</td>
</tr>
<tr>
<td>Overall quality of life</td>
<td>77.5 (50-82.5)</td>
<td>57.5 (45-77.5)</td>
<td>77.5 (62.5-82.5)</td>
<td>0.450</td>
</tr>
<tr>
<td>Emotional well-being</td>
<td>80 (56-88)</td>
<td>84 (70-88)</td>
<td>80 (44-88)</td>
<td>0.616</td>
</tr>
<tr>
<td>Energy/fatigue</td>
<td>60 (42-75)</td>
<td>57.5 (45-65)</td>
<td>60 (45-75)</td>
<td>0.615</td>
</tr>
<tr>
<td>Cognitive function</td>
<td>75.5 (60-96.7)</td>
<td>74.7 (58.7-87.6)</td>
<td>80.3 (60-96.7)</td>
<td>0.802</td>
</tr>
<tr>
<td>Medication effects</td>
<td>78.7 (44.3-100)</td>
<td>100 (72.2-100)</td>
<td>70.7 (30.3-88.7)</td>
<td>0.096</td>
</tr>
<tr>
<td>Social function</td>
<td>86 (75-100)</td>
<td>90.5 (68-97.5)</td>
<td>80 (75-100)</td>
<td>0.762</td>
</tr>
<tr>
<td>Overall score</td>
<td>75.3 (63.4-84.1)</td>
<td>76.4 (59.6-82.4)</td>
<td>72.6 (63.4-84.1)</td>
<td>0.802</td>
</tr>
</tbody>
</table>

Median (lower quartile-upper quartile)

In the domain of seizure worry, patients in the examined group were more concerned about the seizures (54.7) compared to the examined group (80), as well as in the overall quality of life (examined group 57.5; control group 77.5).

Patients in the control group complained more in the domain of antiepileptic therapy (score 70.7) than patients in the examined group (score 100). In the other domains: emotional well-being, energy/fatigue, cognitive functioning, and social functioning there were minor deviations between the examined and control groups. However, there were no statistically significant differences between the individual QOLIE-31 questionnaires (this refers to the overall score), both in the total score and in both examined groups (p=0.802).

**DISCUSSION**

The World Health Organization (WHO) defines the quality of life (QoL) as an individual’s perception of their position in the life in the context of the culture and value systems in which they live and concerning their goals, expectations, standards, and concerns (Jacoby et al. 2009, Mahrer et al. 2013).

There are two types of subjective quality of life measures: generic and disease specific measures. While generic measures can be applied to a wide variety of patients, specific instruments are focused on issues related to the individual disease states or patient groups (Duka Glavor et al. 2019).

In assessing the QoL of patients with epilepsy, the emphasis is placed on the factors that have the greatest influence on the QoL of patients with epilepsy such as: time of first seizure, seizure frequency, seizure type, the efficacy of treatment with antiepileptic drugs and undesirable effects of antiepileptic drugs (Guekht et al. 2007, Jacoby et al. 2009, Mahrer-Imhof et al. 2013). Mood disorders represent a frequent psychiatric comorbidity in epilepsy with adverse consequences for health-related quality of life (Wiglusz et al. 2012).

One of the important factors is also the influence of preoperative and operative treatment on the QoL of patients with drug resistant epilepsy. One way to monitor the effect of preoperative treatment and applied treatment on the QoL of patients with drug resistant epilepsy is through the questionnaire such as QOLIE-31.
The goal of resective epilepsy surgery is long-term seizure freedom. Seizure-free rates are lower in patients with nonlesional neocortical resections. Epileptogenic zones are often distributed in the cortex, but vary from person to person, and sometimes may reside in the deep structure of the brain (Blümcke 2011, Petelin Gadže 2017). Surgical management of extratemporal lobe epilepsy is mainly applicable for patients who had drug resistant epilepsy induced by focal cortical dysplasias (FCD) (Blümcke 2011).

FCD may be subtle, sometimes meticulous inspection will reveal mild cortical thickening or an unusually deep sulcus, but special image analysis techniques can help (Blümcke 2011). Invasive video-EEG can more precisely delineate the extent of a neocortical epileptogenic zone and its relationship to areas of the eloquent functional cortex (Blümcke 2011).

Quality of life in patients with drug resistant epilepsy improved after surgery of FCD, but improved the most in patients who were seizure-free following surgery (Blümcke 2011, Mohammed et al. 2012, Jobst et al. 2015).

In our prospective clinical cross-sectional study we have reported the short outcomes of QoL questionnaire, QOLIE-31, concerning clinical variables - seizure worry, overall quality of life, emotional well-being, energy/fatigue, cognitive function, medication effects and social function. We studied the difference among QOLIE-31 domains between the patients undergoing invasive EEG monitoring and those who did not. Depending on the present data patients in the examined group were more concerned about the seizures (54.7), and in the overall quality of life (57.5), compared to the examined group, but there was no statistically significant difference between individual QOLIE-31 questionnaires, as well as between the two groups of respondents.

Apart from the study of McKhann et al. 2000 on the importance of performing invasive EEG monitoring, and the study of Fong et al. 2012, and Hader et al. 2013 on possible complications after performing invasive EEG monitoring such as bleeding, CSF leak, ischemic lesions or infections, we did not find any published study that would investigate the quality of life of patients with drug resistant epilepsy following invasive EEG monitoring and using scale QOLIE - 31 that we can compare with our results. In our group of patients, during and after invasive EEG monitoring, there were no complications after performed treatment.

CONCLUSION

The presented study is the first of its kind to investigate the impact of invasive EEG monitoring followed by resective neurosurgical treatment on the quality of life in patients with drug resistant epilepsy using the scale QOLIE - 31.

During and after the invasive EEG monitoring, there were no complications in the sense of bleeding, ischemic lesions or infections after the performed treatment. There was no statistically significant difference between individual QOLIE-31 questionnaires, as well as between the two groups of respondents.

At this time we cannot conclude that there is a significant difference in the QOLIE 31 in those patients compared to the group of patients with drug resistant epilepsy who had not undergone neurosurgical procedures. Therefore, we will continue to follow QOLIE-31 in our patients and include a new one in the study in the future.

Acknowledgements:

We are thankful to our colleagues for their support in this research:
University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Department of Neurology, Referral Centre of the Ministry of Health of the Republic of Croatia for Epilepsy: Assoc. Prof. S. Hajnšek, M.D., Ph.D.; Assoc. Prof. Z. Poljakov, M.D., Ph.D.; S. Nankovic, M.D.; V. Sulentic, M.D.; I. Cajic, M.D.; A Bujan Kovac, M.D.; Assoc. Prof. M. Krbot Skoric, EE., Ph.D.; Assist. Prof. V. Isgum EE, Ph.D.
University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Department of Diagnostic and Interventional Radiology: Assoc. Prof. Marko Rados, M.D., Ph.D.; Assoc. Prof. Milan Rados, M.D., Ph.D.; Assoc. Prof. D. Ozretic M.D., Ph.D.; Assist. Prof. G Pavlisa, M.D., Ph.D.
University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Department of Neurosurgery: Prof. Josip Paladin, M.D., Ph.D.; Andrej Desnica, M.D.; Jakob Nemir, M.D., Ph.D.
University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Medical Library Rebro: Prof. Arijana Hajnšek Čaklec.
University Hospital Centre Split, Department of Neurology: Prof. Lidija Sodic, M.D., Ph.D.

Conflict of interest : None to declare.

Contribution of individual authors:

Dragana Mijatović: study design of the article, data collection, literature searches, writing the manuscript, statistical analysis and interpretation of results, approval of the final version.
Željka Petelin Gadže: study design, revisioning the manuscript, approval of the final version.
Filip Derke: data collection, literature searches, approval of the final version.
Goran Mrak: data collection, literature searches, approval of the final version.
Ratimir Petrović: revisioning the manuscript, approval of the final version.
Andrica Lekić: statistical analysis and interpretation of results, approval of the final version.
References


10. Lušić I, Džamonja G, Titlić M et al: Psychometric Validation of the Croatian Version of the Quality of Life in Epilepsy Inventory (QOLIE-31), University of Split, Split University Hospital Centre, Department of Neurology, Split, Croatia, Coll Antropol 2011; 35:1177-1184

11. Fahrer-Inhof R, Jäggli S, Bonomo A: Quality of life in adult patients with epilepsy and their family members.


